High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry

Massimo Martino*, Francesco Lanza, Lorenzo Pavesi, Mustafa Ozturk, Didier Blaise, Ruben Leno Nunez, Hendricus Schouten, Alberto Bosi, Ugo De Giorgi, Daniele Generali, Giovanni Rosti, Andrea Necchi, Andrea Ravelli, Carmelo Bengala, Manuela Badoglio, Paolo Pedrazzoli, Marco Bregni

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had >= 10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at .9% between 2001 and 2005, whereas secondary tumor-related mortality was .9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors,
Original languageEnglish
Pages (from-to)475-481
JournalBiology of Blood and Marrow Transplantation
Issue number3
Publication statusPublished - Mar 2016


  • Autologous hematopoietic stem cell transplantation
  • High-dose chemotherapy
  • High-risk breast cancer

Cite this